Back to Search
Start Over
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF THE SAFETY AND EFFICACY OF PLASMID DNA EXPRESSING 2 ISOFORMS OF HEPATOCYTE GROWTH FACTOR IN PATIENTS WITH CRITICAL LIMB ISCHEMIA
- Source :
- Journal of the American College of Cardiology. (12):A2092
- Publisher :
- American College of Cardiology Foundation. Published by Elsevier Inc.
-
Abstract
- Hepatocyte growth factor (HGF) has shown promise in treating patients with critical limb ischemia (CLI). We performed this phase II study to assess the safety and efficacy of the intramuscular (IM) injection of VM202, plasmid DNA expressing 2 isoforms of HGF, in CLI patients. We enrolled 52
- Subjects :
- Gene isoform
Pathology
medicine.medical_specialty
business.industry
Phases of clinical research
Critical limb ischemia
Pharmacology
Placebo
body regions
Double blind
Plasmid dna
Multicenter trial
Medicine
Hepatocyte growth factor
medicine.symptom
business
Cardiology and Cardiovascular Medicine
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 07351097
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi.dedup.....f154fd45a8175e5b8fcdcdd31780f94a
- Full Text :
- https://doi.org/10.1016/S0735-1097(14)62095-7